Swiss Regulators Approves Use Of Platelet With Cerus’ Intercept Blood System

Cerus has reported that the Swiss regulatory body, Swissmedic, has approved the use of platelet components treated with Cerus’ Intercept Blood System. The approval extends permitted storage time for platelets to seven days with Intercept treatment, compared to five days without treatment.

Reportedly, the regulatory review process by Swissmedic is similar to the regulatory processes in France (Afssaps) and Germany (Paul Ehrlich Institute), in which Intercept-treated blood components have been approved as a biologic for patient use.

Earlier, Cerus had received CE mark approval for its Intercept platelet and plasma systems, which allows Cerus to sell the systems in the EU.